Abstract STING (Stimulator of Interferon Genes) agonists have emerged as promising agents
in the field of cancer immunotherapy, owing to their excellent capacity to activate the innate …

Intravenously administered cyclic dinucleotides and other STING agonists are hampered by
low cellular uptake and poor circulatory half-life. Here we report the covalent conjugation of …

Adjuvants are of critical value in vaccine development as they act on enhancing
immunogenicity of antigen and inducing long‐lasting immunity. However, there are only a …

Integrating multimodal neuro-and nanotechnology-enabled precision immunotherapies with
extant systemic immunotherapies may finally provide a significant breakthrough for …

Patients diagnosed with osteosarcoma undergo extensive surgical intervention and
chemotherapy resulting in dismal prognosis and compromised quality of life owing to poor …

Cancer vaccines, which activate the immune system against a target antigen, are attractive
for prostate cancer, where multiple upregulated protein targets are identified. However …

Glioblastoma (GBM) is a primary malignant brain tumor with limited therapeutic options. One
promising approach is local drug delivery, but the efficacy is hindered by limited diffusion …

Recent advances in cancer immunotherapy have accomplished clinical successes in certain
cancer models over the past decade. However, cancer treatments with adoptive cell transfer …

In nanomedicine, the cellular export of nanomaterials has been less explored than uptake.
Traditionally viewed in a negative light, recent findings highlight the potential of …

After development for more than ten years, stimulator of interferon genes (STING), a
representative of pattern recognition receptors (PRRs), is now entering the stage of …